NCT04014335 - A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

February 8, 2024

Study Completion Date

April 11, 2024

Conditions

Primary IgA Nephropathy

Interventions

DRUG

IONIS-FB-LRx

Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.

Trial Locations (7)

2065

IONIS Investigative Site, St Leonards

2170

IONIS Investigative Site, Liverpool

3050

IONIS Investigative Site, Parkville

8011

IONIS Investigative Site, Christchurch

168582

IONIS Investigative Site, Singapore

V6Z 1Y6

IONIS Investigative Site, Vancouver

M4G 3E8

IONIS Investigative Site, Toronto